Co-founded by Jennifer Doudna and Fyodor Urnov, the company intends to simultaneously develop many gene editing treatments for rare conditions by using the agency’s “plausible mechanism” pathway.
Prof. Lukas Dow, biochemistry, and his team published a study in Nature on Aug. 16, detailing a new, more specific gene editing tool that they created to study cancer mutations through preclinical ...
"Regulatory flexibility must be tailored for cell and gene therapies," commented FDA Commissioner Marty Makary. "These are ...
A major medical milestone took place in May 2025, when doctors at the Children’s Hospital of Philadelphia used CRISPR-based gene editing to treat a child with a rare genetic disorder. Unlike earlier ...
Volatile macroeconomic events are magnified in life science and healthcare applications, which are capital intensive, long-term investments with associated regulatory, safety, and commercial risks.
Urnov is a professor of molecular therapeutics at the University of California, Berkeley, and a director at its Innovative Genomics Institute. In May, news broke of a biomedical first: the on-demand ...
A baby born with a rare and dangerous genetic disease is growing and thriving after getting an experimental gene editing treatment made just for him. Researchers described the case in a new study, ...
A baby born with a rare and dangerous genetic disease is growing and thriving after getting an experimental gene editing treatment made just for him. Researchers described the case in a new study, ...
Genome Editing Market Genome Editing Market Dublin, Jan. 22, 2026 (GLOBE NEWSWIRE) -- The "Genome Editing Market - Global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results